These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
219 related articles for article (PubMed ID: 8390656)
21. Elevated preoperative serum ICTP is a prognostic factor for overall and disease-free survival in breast cancer. Keskikuru R; Bloigu R; Risteli J; Kataja V; Jukkola A Oncol Rep; 2002; 9(6):1323-7. PubMed ID: 12375042 [TBL] [Abstract][Full Text] [Related]
22. Signet ring cell histiocytosis in axillary lymph nodes: a sheep in wolves' clothing? A potentially under-recognized pitfall in the diagnosis of metastatic breast cancer. Pathi R; Lawrence WD; Barroeta JE Breast J; 2009; 15(3):302-3. PubMed ID: 19645788 [No Abstract] [Full Text] [Related]
23. Optimal management of ductal carcinoma in situ of the breast. Sakorafas GH; Farley DR Surg Oncol; 2003 Dec; 12(4):221-40. PubMed ID: 14998563 [TBL] [Abstract][Full Text] [Related]
24. The prognostic significance of the percentage of positive/dissected axillary lymph nodes in breast cancer recurrence and survival in patients with one to three positive axillary lymph nodes. Truong PT; Berthelet E; Lee J; Kader HA; Olivotto IA Cancer; 2005 May; 103(10):2006-14. PubMed ID: 15812825 [TBL] [Abstract][Full Text] [Related]
25. Ductal carcinoma in situ arising in an epithelial inclusion within an axillary lymph node. Srinivasan B; Allan CP; Armes JE Pathology; 2007 Apr; 39(2):268-9. PubMed ID: 17454760 [No Abstract] [Full Text] [Related]
26. Core biopsy diagnosis of ductal carcinoma in situ: an indication for sentinel lymph node biopsy. Mittendorf EA; Arciero CA; Gutchell V; Hooke J; Shriver CD Curr Surg; 2005; 62(2):253-7. PubMed ID: 15796952 [TBL] [Abstract][Full Text] [Related]
28. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival. Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124 [TBL] [Abstract][Full Text] [Related]
29. Intracytoplasmic lumina in breast carcinoma: a helpful histopathologic feature. Battifora H Arch Pathol; 1975 Nov; 99(11):614-7. PubMed ID: 179516 [TBL] [Abstract][Full Text] [Related]
30. [The role of sentinel lymph node biopsy in breast cancer non-invading-duct]. Török K; Péley G; Mátrai Z; Bidlek M; Szabó E; Sinkovics I; Polgár C; Farkas E; Orosz Z; Köves I Magy Seb; 2006 Jun; 59(3):173-8. PubMed ID: 16937792 [TBL] [Abstract][Full Text] [Related]
31. Tumour location is not an independent prognostic factor for survival following a diagnosis of breast cancer. Jayasinghe UW; Boyages J Breast; 2009 Feb; 18(1):41-6. PubMed ID: 19028098 [TBL] [Abstract][Full Text] [Related]
32. The relevance of occult axillary micrometastasis in ductal carcinoma in situ: a clinicopathologic study with long-term follow-up. Lara JF; Young SM; Velilla RE; Santoro EJ; Templeton SF Cancer; 2003 Nov; 98(10):2105-13. PubMed ID: 14601079 [TBL] [Abstract][Full Text] [Related]
33. Long-term morbidity of patients with early breast cancer after sentinel lymph node biopsy compared to axillary lymph node dissection. Schulze T; Mucke J; Markwardt J; Schlag PM; Bembenek A J Surg Oncol; 2006 Feb; 93(2):109-19. PubMed ID: 16425290 [TBL] [Abstract][Full Text] [Related]
34. [Ductal carcinoma in situ of the breast with microinvasion. Role of sentinel lymph node biopsy]. Le Bouëdec G; de Lapasse C; Mishellany F; Chêne G; Michy T; Gimbergues P; Dauplat J Gynecol Obstet Fertil; 2007 Apr; 35(4):317-22. PubMed ID: 17344087 [TBL] [Abstract][Full Text] [Related]
35. Cancer of the breast in young women. Molnár L; Besznyák I; Köves I Acta Chir Hung; 1995-1996; 35(1-2):5-11. PubMed ID: 8659239 [TBL] [Abstract][Full Text] [Related]
36. Axillary lymph node dissection in pT1 breast cancer: a retrospective analysis of 315 patients and review of the literature. Witt A; Obwegeser R; Auerbach L; Tempfer C; Yavuz D; Kubista E Wien Klin Wochenschr; 2002 Jun; 114(10-11):387-90. PubMed ID: 12708092 [TBL] [Abstract][Full Text] [Related]
37. Mammographically detected, clinically occult ductal carcinoma in situ treated with breast-conserving surgery and definitive breast irradiation. Solin LJ; McCormick B; Recht A; Haffty BG; Taylor ME; Kuske RR; Bornstein BA; McNeese M; Schultz DJ; Fowble BL; Barrett W; Yeh IT; Kurtz JM; Amalric R; Fourquet A Cancer J Sci Am; 1996; 2(3):158-65. PubMed ID: 9166516 [TBL] [Abstract][Full Text] [Related]
38. [Clinical analysis of resectable breast cancer: a report of 6 263 cases]. Yang MT; Rong TH; Huang ZF; Zeng CG; Long H; Fu JH; Lin P; Wang X; Wang SY; Wang X; Tang J Ai Zheng; 2005 Mar; 24(3):327-31. PubMed ID: 15757535 [TBL] [Abstract][Full Text] [Related]
39. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma. Machiavelli MR; Romero AO; Pérez JE; Lacava JA; Domínguez ME; Rodríguez R; Barbieri MR; Romero Acuña LA; Romero Acuña JM; Langhi MJ; Amato S; Ortiz EH; Vallejo CT; Leone BA Cancer J Sci Am; 1998; 4(2):125-31. PubMed ID: 9554929 [TBL] [Abstract][Full Text] [Related]
40. The incidence and significance of micrometastases in lymph nodes of patients with ductal carcinoma in situ and T1a carcinoma of the breast. Broekhuizen LN; Wijsman JH; Peterse JL; Rutgers EJ Eur J Surg Oncol; 2006 Jun; 32(5):502-6. PubMed ID: 16569492 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]